Pre-market Movers: iBio, Direct Digital Holdings, Nuvation Bio, PaySign, LuxUrban Hotels | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.30 A.M. ET).In the Green iBio, Inc. (IBIO) is up over 86% at $2.14.
Nuvation... ► Artikel lesen |
iBio, Inc.: iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases | - Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments - - iBio to use its patented generative AI/Machine Learning platform to discover, engineer... ► Artikel lesen |
iBio, Inc.: iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka | - Deal includes $1 million upfront and potential future milestone payments - - iBio's proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates - BRYAN... ► Artikel lesen |
Biotech Report: Evotec klettern, Qiagen fest | (shareribs.com) Frankfurt / New York 27.03.2024 - Biotechnologiewerte tendieren am Mittwoch auf breiter Front im Plus. Gesucht sind Evotec und Qiagen. 4SC gibt nach. Auch an der Wall Street überwiegen... ► Artikel lesen |
MyBio Ltd.: MyBio Are the New Exclusive Partner for QIAGEN in Ireland & Northern Ireland | MyBio Ltd., an award-winning specialist Irish life science distribution partner, announces a new exclusive partnership with QIAGEN, a leading global provider, to distribute their leading Life Science... ► Artikel lesen |
Rheinmetall, Vonovia, Munich Re, Qiagen: DAX-Überblick | Der DAX (WKN: 846900) ist weiterhin nicht zu bremsen. Am Dienstag legte das größte deutsche Börsenbarometer knapp 140 Punkte zu und ging +0,54% höher mit 18.399 Punkten aus dem Handel. Gefragt waren... ► Artikel lesen |
Annexon Biosciences: Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones | Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024... ► Artikel lesen |
Annexon Biosciences: Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living... ► Artikel lesen |
Annexon Biosciences: Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases | ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S. ANX007 Global Pivotal Program in... ► Artikel lesen |